CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.

doi:10.1158/0008-5472.CAN-25-1301

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.

Cancer research - 16 Jan 2026

Kreger Bridget T, Liang Yanke, Reilly Nicole M, Spears Meghan E, Scott William A, Simard Jeffrey R, Li Ping, Chaturvedi Prasoon, Agafonov Roman V, Stephenson Jacob, Baddour Joelle, Hart June A, Bahadduri Praveen M, Riegel Logan, Cole Kyle, Lobbardi Riadh, Follmer Nicole E, Hurh Eunju, Good Andrew, Fitzgerald Mark E, Patel Joe, Jackson Katrina L, Poling Laura L, Phillips Andrew J, Naveschuk Christopher G, Fisher Stewart L, Pollock Roy M, Sowa Mathew E

Abstract excerpt

Currently approved BRAF inhibitors (BRAFi) have achieved impressive efficacy in BRAFV600-mutant cancers. However, the clinical benefit of BRAFis is limited by several factors, including vulnerability to RAF dimer-driven resistance mechanisms, poor brain penetration, and side effects arising from paradoxical activation of MAPK signaling in normal tissue. In this study, we aimed to overcome these limitations by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 41150906
DOI: 10.1158/0008-5472.CAN-25-1301

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.PMID 41150906Read ↗

Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders.Semantic proximity Read ↗

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read ↗

Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation.Semantic proximity Read ↗

Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.Semantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

Mutant-selective Degradation by BRAF-targeting PROTACsSemantic proximity Read ↗

Mutant-selective degradation by BRAF-targeting PROTACs.Semantic proximity Read ↗

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022Semantic proximity Read ↗

Functional characterization of a PROTAC directed against BRAF mutant V600E.Semantic proximity Read ↗

A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.Semantic proximity Read ↗

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.Semantic proximity Read ↗

Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.